MannKind Receives $30.6 Million From Sanofi

   PDF    Add to Briefcase

VALENCIA, Calif., Jan. 09, 2017 (GLOBE NEWSWIRE) -- MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) today confirmed that it received $30.6 million from Sanofi on January 6, 2017, representing the balance of the accelerated insulin "put" option previously exercised by MannKind.  This payment was made pursuant to a previously disclosed agreement reached with Sanofi on November 9, 2016. 

About MannKind Corporation

MannKind Corporation (NASDAQ:MNKD) (TASE:MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes. MannKind maintains a website at http://www.mannkindcorp.com to which MannKind regularly posts copies of its press releases as well as additional information about MannKind. Interested persons can subscribe on the MannKind website to e-mail alerts that are sent automatically when MannKind issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the website.

Company Contact:
Rose Alinaya
SVP, Finance
661-775-5300
ralinaya@mannkindcorp.com

MNKD

Exchange:
NASDAQ GM and TASE(US Dollar)

Price: 1.98

Change: 0.04 (1.980%)

Volume: 2,551,696

Data as of
09/20/2017 04:00 PM ET .
Minimum 20 minute delay.

Refresh Quote >

Locations

Learn more about MannKind's offices in the United States

Learn More